Minimal Residual Disease (MRD) for Early Detection of Cancer Recurrence (Signatera™, Haystack MRD™)
Despite surgical resection and systemic therapy (chemotherapy, immunotherapy), residual microscopic disease often remains undetected, contributing to cancer recurrence. This persistent state, termed Minimal Residual Disease (MRD), is pivotal for assessing treatment efficacy and predicting relapse risk.
Signatera™ is a personalized, tumor-informed circulating tumor DNA (ctDNA) assay designed for highly sensitive detection of Minimal Residual Disease (MRD) through non-invasive blood-based testing. Unlike standard ctDNA panels, Signatera creates a customized assay for each patient, targeting 16 tumor-specific somatic mutations identified from that individual's primary tumor tissue.
The assay demonstrates exceptional analytical sensitivity, capable of detecting one mutant molecule per 5 mL of plasma, enabling the detection of residual disease at molecular levels before clinical or radiographic recurrence becomes apparent. Signatera offers a positive predictive value (PPV) exceeding 98% for relapse risk across multiple solid tumors, including colorectal, breast, lung, bladder, and melanoma. It supports real-time, longitudinal monitoring, allowing for the dynamic assessment of tumor burden post-treatment or post-surgery. Clinical validation studies have consistently shown its utility in informing adjuvant therapy decisions, risk stratification, and surveillance strategies across a variety of cancer types.
Haystack MRD™ Baseline - Haystack MRD™ is a tumor-informed minimal residual disease (MRD) test that analyzes circulating tumor DNA (ctDNA) in the blood of patients with cancer or a previous diagnosis of cancer. The test requires identification of tumor-specific mutations for the development of a personalized ctDNA assay (Haystack MRD™ Baseline). The personalized assay is used to measure ctDNA to identify the presence of cancer in an initial blood sample and at subsequent timepoints (Haystack MRD™ Monitoring).
- Early detection of cancer recurrence prior to radiographic evidence
- Informs adjuvant therapy decisions (e.g., escalation or de-escalation)
- Assists in risk stratification after surgery
- Reduces unnecessary imaging and overtreatment when MRD-negative
Positive Result
- Detectable ctDNA; suggests the presence of residual disease and a significantly higher risk of clinical recurrence.
- Clinical implication: May prompt initiation or intensification of adjuvant therapy.
Negative Result
- No detectable ctDNA; associated with a low risk of recurrence.
- Clinical implication: May support de-escalation of therapy or observation alone.
Negative for MRD (Based on the comparison of mutation profiles between patient and normal matched DNA sequence)
Tumor Tissue
- FFPE block or unstained slides (preferred for initial tumor profiling)
Matched Normal Sample
- Peripheral blood (EDTA tube)
Follow-up Samples
- Peripheral blood (EDTA tube) drawn for longitudinal monitoring (plasma separated within 6 hours).
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Mol Diagn Ther. 2021 Nov;25(6):757-774. [PMID: 34725800]
- Cells. 2023 Apr 1;12(7):1068. doi: 10.3390/cells12071068. [PMID: 37048141]
- Sci Transl Med. 2016;8(346):346ra92-346ra92. [PMID: 27384348]
- Ann Oncol. 2021;32(2):229-239. doi:10.1016/j.annonc.2020.11.007. [PMID: 33232761]
- Front Oncol. 2021 Nov 18;11:763790. [PMID: 34868984]
- JAMA Oncol. 2019;5(12):1710. doi:10.1001/jamaoncol.2019.3616. [PMID: 31621801]
- Front Oncol. 2022 Feb 2;12:786451. [PMID: 35186734]
- Cancers (Basel). 2022 Jun 23;14(13):3078. [PMID: 35804850]
- JAMA Oncology. 2019;5(8):1124-1131. [PMID: 31070691]
- Nature. 2017,545:446–451. [PMID: 28445469]
- Natera Signatera Official Website: https://www.natera.com/oncology/signatera-advanced-cancer-detection/